A New Piece Added to the Whipple Puzzle: Tropheryma whipplei Primary Infection with Bacteremia and Cough by Greub, Gilbert
522 • CID 2010:51 (1 September) • EDITORIAL COMMENTARY
E D I T O R I A L C O M M E N T A R Y
A New Piece Added to the Whipple Puzzle: Tropheryma
whipplei Primary Infection with Bacteremia and Cough
Gilbert Greub
Institute of Microbiology and Service of Infectious Diseases, University of Lausanne and University Hospital Center, Lausanne, Switzerland
(See the article by Fenollar et al, on pages 515–521.)
In 1907, when the first case of Whipple
disease was described by George Whipple,
the clinical presentation of the disease, al-
though not considered to be of infectious
origin, already included cough and diar-
rhea [1]. This index patient had a chronic
form of the disease, coined here as late-
onset Whipple disease. During the past
century, Whipple disease has been consid-
ered to be a rare and chronic disease,
mainly affecting white, middle-aged men
and presenting mainly as diarrhea, weight
loss, steatorrhea, arthralgia, lymphade-
nopathy, anemia, and, to a lesser extent,
neurologic impairments, ocular involve-
ment, and/or endocarditis [2]. The visu-
alization by electron microscopy of rods
in intestinal biopsy specimens suggested
that Whipple disease was of microbial or-
igin [3, 4], a hypothesis confirmed in the
1990s by sequencing the 16S ribosomal
RNA encoding gene of the causative bac-
teria [5, 6], named Tropheryma whipplei
[7].
However, our understanding of the ep-
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idemiology, mode of transmission, path-
ogenesis, and natural history of Whipple
disease remained largely incomplete, being
impaired by the few diagnostic tools avail-
able. Indeed, the diagnosis still mainly re-
lies on histologic analysis (periodic acid–
Schiff–positive macrophages), polymerase
chain reaction (PCR), and immunohis-
tochemical analysis [2, 8, 9]. Culture
proved to be challenging because of the
slow replication rate of the bacteria (gen-
eration time of∼18 days) [10], and culture
is still currently performed only in a few
specialized laboratories. Moreover, devel-
opment of serologic tools has been com-
plicated by the paradoxical lack of anti-
body response in serum samples taken
from patients with late-onset Whipple dis-
ease, likely related to glycosylation of bac-
terial antigens, which allows the bacteria
to mask its own major antigens [11].
The mode of transmission and the clin-
ical presentation of acute T. whipplei pri-
mary infection was partially uncovered re-
cently. Fecal-oral transmission was sug-
gested by the amplification of bacterial
DNA from sewage and from feces of sewer
workers and by the higher prevalence
among this occupationally exposed pop-
ulation [12, 13]. Moreover, the coinciden-
tal presence of the bacteria with other en-
teric pathogens, such as Giardia lamblia
[14], further supported the hypothesis of
a fecal-oral transmission. Although fecal-
oral primary infection might be asymp-
tomatic, Raoult et al [15] hypothesized
that T. whipplei might cause gastroenter-
itis. They thus studied prospectively
French children with and without gastro-
intestinal symptoms, convincingly dem-
onstrating that T. whipplei may indeed
represent an agent of gastroenteritis be-
cause both increased immunoglobulin M
titers and higher bacterial DNA load were
observed among cases.
The same group reported a high prev-
alence (44%) of T. whipplei DNA in stools
from healthy 2- to 10-year-old children
living in Ndiop and Dielmo, 2 rural vil-
lages located in the south of Senegal [16].
Suspecting an ongoing outbreak of acute
Whipple disease, Fennolar et al [17] un-
dertook the study reported in this issue
and identified 13 bacteremic cases among
febrile patients living in these 2 villages.
Interestingly, most cases were identified
during the dry season (December to Jan-
uary) and among children (np10). How-
ever, contrary to what has been expected,
the bacteremia was not associated with di-
arrhea (np1) but rather with cough (n
p10) and sleep disorders (np5). This
study thus adds an important new piece
to the Whipple puzzle that makes it pos-
sible to consider febrile bacteremia and
cough as possible common clinical pre-
sentations of acute T. whipplei infection.
This new information completely changes
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Figure 1. A new piece added to the puzzle describing the natural history of Whipple disease. A, Interhuman transmission likely takes place through fecal-
oral contamination. However, infection might also possibly follow exposure to human saliva and/or aerosols or be associated with yet unknown environmental
or zoonotic risks. B, Primary infection might be asymptomatic but may also present as a febrile illness associated with cough and sleep disorders, as demonstrated
by Fenollar et al. in this issue [17]. This additional piece added to the Whipple puzzle also supports previous reports that suggest a role of T. whipplei as an
agent of pneumonia [18, 19]. Nevertheless, primary infection might also present as a common gastroenteritis [15] and some yet unknown additional syndromes.
C, Only a limited number of patients will later develop focal or multifocal clinical manifestation of late-onset Whipple disease. Immunogenetic factors are likely
important in this rare pathological evolution [23]. Please note that the list of manifestations provided here is not exhaustive. Focal manifestations such as
prodromal arthritis may precede classic multifocal Whipple disease for years. D and E, Most infected patients would either became asymptomatic carriers or
completely recover from T. whipplei primary infection. Whether asymptomatic carriers are at risk to later develop clinical manifestations of focal or multifocal
late-onset Whipple disease is yet unknown.
the way we perceive the pathogenesis and
natural history of Whipple disease. Thus,
in addition to the rare late-onset Whipple
disease that includes both focal and mul-
tifocal clinical manifestations, T. whipplei
also causes an acute common illness, likely
corresponding to primary infection with
bacteremia, cough, and/or gastroenteritis
(Figure 1).
The absence of T. whipplei DNA in all
investigated water sources present in
Ndiop and Dielmo villages suggested hu-
man-to-human transmission. Although
primary infection after oral-oral and/or
fecal-oral transmission is suggested by the
presence of T. whipplei DNA in both sali-
va and stools from healthy individuals
(asymptomatic carriers), the clinical pre-
sentation observed by Fenollar et al [17]
among 10 of the 13 bacteremic patients
(ie, fever and cough) might also possibly
reflect an airborne transmission. Thus,
respiratory tract infection might be con-
secutive to inhalation of infected droplets,
whereas gastroenteritis might follow in-
gestion of infectious particles.
Recent evidence suggests a role of T.
whipplei as an agent of pneumonia [18,
19]. In 1 of these reports, T. whipplei was
identified in 6 (3%) of 210 bronchoalveo-
lar lavages tested [19]. Notably, 3 patients
experienced aspiration pneumonia. Be-
cause T. whipplei may be present in the
saliva of asymptomatic persons [20, 21],
it has been proposed that this gram-pos-
itive rod could contribute to aspiration
pneumonia along with other bacteria pres-
ent in the oropharyngeal microbiota [19].
Conversely, the presence of T. whipplei
DNA in the saliva of asymptomatic pa-
tients complicates the interpretation of
DNA positivity in bronchoalveolar lavages
(possible contamination of the respiratory
sample with saliva). Moreover, in the work
of Bousbia et al [19], T. whipplei was gen-
erally not the only detected agent. In that
context, the documentation by Fenollar et
al [17] of an association between T. whip-
plei bacteremia and cough is important
because it further supports a role of T.
whipplei as a possible agent of lower res-
piratory tract infection.
One of the main limitations of the work
performed by Fenollar et al [17] is the
absence of a control group among Sene-
galese patients. Indeed, the negative results
of the PCR performed on the French con-
trols support an absence of PCR contam-
ination but do not rule out horizontal
contamination of the samples during the
early phase of DNA extraction performed
in Senegal.
Despite this limitation, the study per-
formed by Fenollar et al [17] represents a
pivotal work that opens new questions
that need to be addressed in the near fu-
ture. The prevalence of T. whipplei bac-
teremia and associated clinical manifes-
tations needs to be defined thoroughly in
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various populations (children, adults, and
immunocompromised individuals) from
different geographical areas. The preva-
lence of T. whipplei pneumonia [19] and
gastroenteritis [15] also needs to be stud-
ied in different settings. These studies may
help to identify the reservoir and mode of
transmission of T. whipplei. Although hu-
man-to-human transmission is likely, en-
vironmental (food, water, and soil) and/
or zoonotic risks should also be searched
for.
The documentation of T. whipplei bac-
teremia also raises important treatment is-
sues. Apparently, all 13 bacteremic patients
evolved favorably even though most of
them were left untreated [17]. Neverthe-
less, we may wonder whether such bac-
teremia needs to be treated (1) to further
improve short-term outcome, (2) to re-
duce transmission, (3) to avoid asymp-
tomatic carriage, and/or (4) to prevent
late-onset T. whipplei infection in some of
these patients. The latter question will only
be solved by starting a prospective ran-
domized cohort study of any patients
identified in similar outbreaks of acute in-
fection. Randomization for treatment ver-
sus absence of treatment includes an im-
portant ethical issue given the unknown
risk of development of severe difficult-
to-treat late-onset Whipple disease, such
as encephalitis or endocarditis. The un-
treated group will be pivotal to define the
natural history of Whipple disease and to
identify factors associated with the rare de-
velopment of late-onset Whipple disease.
Given the absence of correlation of T.
whipplei genotypes with clinical presen-
tation [22], host factors are likely to play
a major role. Some immunogenetic factors
have recently been identified [23], and
these hosts factors may explain why such
a common primary infection with bacte-
remia, pneumonia, and/or gastroenteritis
only rarely causes focal or multifocal late-
onset Whipple disease. Genetic factors
may also potentially explain why late-on-
set Whipple disease has been reported
more frequently among white, male in-
dividuals. In addition to genetic factors,
the apparent discrepancy between the rel-
atively high prevalence of acute T. whipplei
infection in Africa and the near absence
of classic Whipple disease among African
residents might also be partially explained
by the lower rate of recognition of late-
onset Whipple disease.
In conclusion, the landmark article by
Fenollar and colleagues published in this
issue of Clinical Infectious Diseases should
be added to the list of major contributions
to the understanding of Whipple disease
because it provides the first evidence of T.
whipplei–associated bacteremia and rep-
resents a missing piece of the primary-
infection Whipple puzzle.
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